Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Express Scripts
Colorcon
Boehringer Ingelheim
Medtronic

Last Updated: March 26, 2023

Details for New Drug Application (NDA): 016822


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA 016822 describes FREAMINE III 8.5% W/ ELECTROLYTES, which is a drug marketed by B Braun and is included in one NDA. It is available from one supplier. Additional details are available on the FREAMINE III 8.5% W/ ELECTROLYTES profile page.

The generic ingredient in FREAMINE III 8.5% W/ ELECTROLYTES is amino acids; magnesium acetate; phosphoric acid; potassium acetate; potassium chloride; sodium acetate. There are three hundred and fifty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amino acids; magnesium acetate; phosphoric acid; potassium acetate; potassium chloride; sodium acetate profile page.
Pharmacology for NDA: 016822
Suppliers and Packaging for NDA: 016822
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FREAMINE 8.5% amino acids INJECTABLE;INJECTION 016822 NDA B. Braun Medical Inc. 0264-9010 0264-9010-55 6 CARTON in 1 CASE (0264-9010-55) / 1 CONTAINER in 1 CARTON / 1000 mL in 1 CONTAINER
FREAMINE HBC 6.9% amino acids INJECTABLE;INJECTION 016822 NDA B. Braun Medical Inc. 0264-9010 0264-9010-55 6 CARTON in 1 CASE (0264-9010-55) / 1 CONTAINER in 1 CARTON / 1000 mL in 1 CONTAINER

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength8.5% (8.5GM/100ML)
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength8.5% (8.5GM/100ML)
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength3%;54MG/100ML;40MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Baxter
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.